Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568516 | 0.92 | SMN1; SMN2 (0.53) | SLC13A5TAAR1MAOBFDFT1FGFR2 | |
| SCHEMBL2570658 | 0.91 | TSHR (0.56) | SLC13A5TAAR1MAOBFDFT1FGFR2 | |
| SCHEMBL198917 | 0.86 | KDM4E (0.59) | SLC13A5KDM4EFDFT1RXRARXRB | |
| SCHEMBL1337028 | 0.85 | KDM4E (0.57) | SLC13A5TAAR1MAOBKDM4EFDFT1 | |
| SCHEMBL15473215 | 0.84 | KMT2A (0.57) | SLC13A5KDM4ERXRARXRBKMT2A | |
| SCHEMBL15257247 | 0.84 | KEAP1 (0.58) | TAAR1MAOBKDM4ECSNK2A1KMT2A | |
| SCHEMBL2538910 | 0.83 | DHFR (0.54) | TAAR1MAOBKDM4ECSNK2A1KMT2A | |
| Hydrochloric Acid SCHEMBL20497359 | 0.82 | KEAP1 (0.65) | TAAR1MAOBKDM4ECSNK2A1HRH3 | |
| SCHEMBL2570159 | 0.82 | LSS (0.59) | TAAR1MAOBKDM4EKMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL2540065 | 0.81 | CSNK2A1 (0.53) | TAAR1MAOBKDM4ECSNK2A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | SLC13A5 31/4885TAAR1 2821/4885MAOB 2260/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | SLC13A5 24/4885TAAR1 2908/4885MAOB 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.